It's day three of the Pfizer-Sanofi merger watch. Sanofi-Aventis shares are up 5.5 percent on continued rumors of a Pfizer investment in its business. Now, experts are saying that a Sanofi acquisition wouldn't be prudent for Pfizer--but a partnership would.
If Pfizer just bought a stake in Sanofi, it could share in the French company's revenues. Sanofi would get access to Pfizer's U.S. sales force. And the companies wouldn't have to get the French government's blessing on this sort of deal--a blessing that might be hard to come by.
- read the report from Fortune
Read more on: PfizerÂ | Sanofi-Aventis